Lotus Med S.R.L.
- Address
- lock Available on a paid plan
Cardiovascular Research
The site focuses on atherosclerotic cardiovascular disease, aiming to reduce heart‑related events and improve kidney outcomes in patients with chronic inflammation. Trials evaluate new agents that may prevent heart failure and lower major adverse cardiovascular events.
- Atherosclerosis and plaque progression
- Prevention of heart failure in high‑risk populations
- Cardiovascular safety of metabolic therapeutics
- Inflammation‑driven cardiovascular risk reduction
Lotus Med S.R.L. in Bucharest conducts 15 trials with 17 investigators, integrating cardiovascular science with kidney health research.
Women’s Health
Studies address human papillomavirus infection and breast cancer subtypes, testing novel therapies to clear HPV and improve outcomes for early and triple‑negative breast cancer. The goal is to enhance treatment effectiveness and reduce recurrence.
- Clearance of high‑risk genital HPV
- Adjuvant endocrine therapy in early breast cancer
- Targeted approaches for triple‑negative breast cancer
- Management of pregnancy‑related complications
The department collaborates with local oncology and gynecology units to bring innovative options to female patients.
Immune‑Mediated Disorders
Research includes pediatric and adult moderate to severe plaque psoriasis, evaluating new oral inhibitors and assessing safety, tolerability, and skin‑clearance outcomes. Trials seek to provide better disease control with fewer side effects.
- Pediatric psoriasis treatment evaluation
- Novel JAK inhibitor safety and efficacy
- Immune pathway targeting in inflammatory skin disease
- Long‑term tolerability of systemic psoriasis therapies
Investigators at Lotus Med S.R.L. combine dermatology expertise with immunology to advance care for patients with severe skin disease.
Oncology Trials
The oncology portfolio covers non‑small cell lung cancer and breast cancer, including KRAS‑mutated lung tumors and metastatic triple‑negative disease. Trials compare new targeted agents and immunotherapy combinations to standard chemotherapy, aiming to extend survival and improve response rates.
- Targeted therapies for KRAS‑G12C‑mutant lung cancer
- Combination immunotherapy in advanced NSCLC
- New agents for metastatic triple‑negative breast cancer
- Adjuvant strategies for resected lung cancer
With a multidisciplinary team, Lotus Med S.R.L. supports cutting‑edge cancer research across multiple tumor types.
Metabolism & Nutrition
Trials investigate treatments for obesity and related metabolic disorders, focusing on cardiovascular and renal outcomes. Studies assess whether weight‑loss agents can lower major adverse events and improve overall metabolic health.
- Weight‑loss therapies and cardiovascular risk
- Metabolic syndrome impact on kidney function
- Novel agents for atherosclerotic disease in obese patients
- Prevention of heart failure in overweight individuals
The department integrates nutritional science with cardiometabolic research to address rising rates of obesity in the region.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 33 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Lotus Med S.R.L.
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Subjects with Moderate to Severe Plaque Psoriasis | Bristol-Myers Squibb Services Unlimited Company | Phase III | Recruiting | May 2021 | — |
IMP list
lock Showing 1 of 33 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 3 | Unknown | 2024-06-27 | 2025-11-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.